Profile

Cover photo
Krishan Maggon
Attended PHD
Lives in Geneva, Switzerland & New York, USA
131 followers|32,357 views
AboutPostsPhotosVideos
People
Have him in circles
131 people
Yenti Cang Cun Huan's profile photo
Tatsuo Nakagawa's profile photo
Walker Grace's profile photo
Narayana Rao's profile photo
L'Infographe Lahaye's profile photo
Nico Peruzzi's profile photo
Bradley Johnson's profile photo
Cathryn Brimhall's profile photo
OBGYN.net's profile photo
Work
Occupation
Consultant Pharmaceutical Biotechnology R&D & Advisor
Employment
  • Consultant Pharmaceutical Biotechnology R&D & Advisor, present
Places
Map of the places this user has livedMap of the places this user has livedMap of the places this user has lived
Currently
Geneva, Switzerland & New York, USA
Story
Tagline
Consultant and Advisor, New Drug Development and R&D
Introduction
                 

International pharma R&D adviser: new drug development, project management, business development, licensing, market introduction/support, contract and external research management and training.  Doctorate in Medical Biochemistry, over 100 publications.

Consultant and Advisor, New Drug Development and
Consultancy in New Drug Development, Licensing and Technology Transfer.

Krishan Maggon

Knol First Year Odyssey

Krishan Maggon Knols

Scoop It


Facebook


Twitter


Linkedin



Education
  • PHD
    Medical Biochemistry
Basic Information
Gender
Male

Stream

Krishan Maggon

Shared publicly  - 
 
A new clinical trial in glioblastoma has been launched based on an innovative immunotherapeutic technique – the CAR T cell which can modify then harness a patient’s own T cells to fight their disease.
1
Add a comment...

Krishan Maggon

Shared publicly  - 
 
Highlights •Aptamers are oligonucleotides that bind targets conceptually similar to antibodies.•Spiegelmers are plasma-stable, nonimmunogenic, mirror-image (l-configured) aptamers.•Spiegelmers were identified against various pharmacologically relevant targets.•Three Spiegelmers are in Phase II studies for diabetic complications and cancer.•Phase IIa data show proof-of-concept for the first Spiegelmer drug emapticap pegol.
1
Add a comment...
Have him in circles
131 people
Yenti Cang Cun Huan's profile photo
Tatsuo Nakagawa's profile photo
Walker Grace's profile photo
Narayana Rao's profile photo
L'Infographe Lahaye's profile photo
Nico Peruzzi's profile photo
Bradley Johnson's profile photo
Cathryn Brimhall's profile photo
OBGYN.net's profile photo

Krishan Maggon

Shared publicly  - 
 
The FDA's approval of cancer immunotherapies that target the PD-1 pathway offers new hope to thousands of patients with advanced cases of cancer..
1
Add a comment...

Krishan Maggon

Shared publicly  - 
 
Sacks and coauthors identify the reasons that US Food and Drug Administration (FDA) marketing approval for new drugs was delayed or denied in drug applications for new molecular entities first submitted to the FDA between 2000 and 2012. Abstract Importance  Some new drug applications fail because of inadequate drug performance and others are not approved because the information submitted to the US Food and Drug Administration (FDA) is unsatisfact...
1
Add a comment...

Krishan Maggon

Shared publicly  - 
 
Highlights •We provide a SWOT analysis of peptide therapeutics and discuss commercial aspects.•We comment on emerging peptide technologies and cell-penetrating peptides.•Multifunctional peptides and peptide drug conjugates are discussed.•We foresee intelligent design and assembly of peptide modules as molecular medicines.•Peptides offer enormous growth potential as future therapeutics.
1
Add a comment...